Noctrix Health Secures $17M Series B to Accelerate Novel Treatment for Restless Legs Syndrome

Restless Legs Syndrome (RLS) represents one of the most prevalent yet undertreated sleep disorders globally, affecting more than 10% of the American adult population. Current treatment options rely heavily on dopaminergic pharmaceuticals, which carry limitations in efficacy and tolerability. Noctrix Health has identified this significant clinical gap and is positioning itself to transform the therapeutic landscape for millions of RLS sufferers worldwide.

Breakthrough Financing and Strategic Partnerships

Noctrix Health has successfully closed a $17 million Series B funding round, marking a pivotal milestone in the company’s development trajectory. The investment was jointly led by Treo Ventures and OrbiMed, with meaningful participation from LivaNova PLC (NASDAQ: LIVN) and existing shareholders. This capital infusion represents strong validation from the investment community regarding Noctrix Health’s clinical strategy and commercial potential.

The financing brings new board members into the leadership circle: Tracy Pappas from Treo Ventures and Chau Khuong from OrbiMed will join the existing board alongside Founder and Chief Executive Officer Shri Raghunathan, PhD, Mudit K. Jain, PhD, and Allan May.

The Noctrix Health Innovation Platform

Founded in 2018 through Stanford University’s Biodesign Program, Noctrix Health has developed a proprietary neuromodulation-based therapeutic approach to address RLS symptoms. Rather than relying on pharmacological interventions, the company’s platform employs wearable neurostimulation technology designed to provide non-invasive, non-pharmacologic relief from the characteristic sensations of tingling and the overwhelming urge to move the lower extremities—symptoms that typically intensify during evening and nighttime hours.

This differentiated approach has earned recognition from regulatory authorities. The U.S. Food & Drug Administration (FDA) has granted Noctrix Health a “Breakthrough Device Designation,” expediting the pathway for clinical evaluation and commercialization of the therapy.

Investor Confidence and Market Outlook

Tracy Pappas, Partner at Treo Ventures, emphasized the company’s potential: “Noctrix Health is drawing on deep clinical expertise to accelerate development of a groundbreaking therapy with transformative potential for the millions struggling with RLS. We are enthusiastic about supporting the company’s growth trajectory.”

Chau Khuong from OrbiMed added: “We have monitored Noctrix Health’s progress with great interest and have been impressed by the technical achievements demonstrated to date. We are eager to collaborate with the team to establish a world-class organization delivering a safe, effective, and non-invasive solution for RLS patients who desperately need alternatives.”

Dr. Raghunathan expressed optimism about the partnership: “We are grateful to partner with such a distinguished investor cohort anchored by OrbiMed and Treo Ventures. This financing equips us with the capital necessary to advance our therapy toward patients who endure the disruptive nightly manifestations of this debilitating condition.”

The $17 million Series B represents Noctrix Health’s commitment to bridging the unmet medical need in sleep disorder treatment and expanding access to innovative, patient-centric solutions for RLS management.